Amgen Stock Dropped by 3.38% as Investors Reassess Valuation Multiples
Amgen Inc's stock (AMGN) dropped by 3.38% on October 1, following a notable intraday volatility and downward pressure from market participants who engaged in profit-taking after a substantial rally.
This downturn was partly due to the company's valuation multiples being at an elevated level, with institutional investors weighing intrinsic cash flow projections against these high valuations.
The stock also faced selling activity as traders adjusted their short-term exposure across defensive assets within the healthcare and biotechnology sectors.
Despite advancing key clinical initiatives, including positive late-stage readouts for its immunology candidate dazodalibep and pediatric study completions for Otezla, investor focus remains on high-stakes pipeline assets such as MariTide in a hyper-competitive obesity landscape.